Eisai Cancer Subsidiary H3 Pushes Toward The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
H3 Biomedicine is using publicly available cancer genomics data to discover compounds that could treat small subsets of patients.
You may also be interested in...
Eisai Parades Pipeline Before Investors During First US R&D Day
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
Eisai Parades Pipeline Before Investors During First US R&D Day
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening
Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.